You are on page 1of 1

64228 Federal Register / Vol. 72, No.

220 / Thursday, November 15, 2007 / Notices

registered attendees badges that must be DC or by fax to (202) 395–6974. Written annual number and trends of severe
worn at all times and returned to comments should be received within 30 adverse events associated with
security prior to exiting the Cohen days of this notice. treatment of LTBI and identify common
Building. characteristics of patients with severe
Registration questions may be Proposed Project
adverse events during treatment of
directed to Experient at National Surveillance for Severe LTBI. Potential correspondents are any
PAguidelines@experient-inc.com (e- Adverse Events Associated with of the 60 reporting areas for the national
mail), (703) 525–8333 x3346 (phone) or Treatment of Latent Tuberculosis TB surveillance system (the 50 states,
(703) 525–8557 (fax). Infection—New, Division of the District of Columbia, New York City,
Dated: November 8, 2007. Tuberculosis Elimination (DTBE), Puerto Rico, and 8 jurisdictions in the
Penelope Slade Royall,
National Center for HIV/AIDS, Viral Pacific and Caribbean). Data will be
Hepatitis, STD, and TB Prevention collected using the data collection form
RADM, USPHS, Deputy Assistant Secretary
for Health, Office of Disease Prevention and
(NCHSTP), Centers for Disease Control for adverse event associated with LTBI
Health Promotion. and Prevention (CDC). treatment (AELT). The AELT form is
[FR Doc. E7–22333 Filed 11–14–07; 8:45 am] Background and Brief Description completed for each reported
BILLING CODE 4150–32–P hospitalization or death related to
Between October 2000 and October treatment of LTBI and contains
2007, 79 patients receiving treatment for
demographic, clinical, and laboratory
DEPARTMENT OF HEALTH AND Latent TB Infection (LTBI) were
information. CDC will analyze and
HUMAN SERVICES reported to the Division of Tuberculosis
periodically publish reports
Elimination (DTBE), Centers for Disease
summarizing national LTBI treatment
Centers for Disease Control and Control and Prevention (CDC) with
adverse events statistics and also will
Prevention severe adverse events to their
conduct special analyses for publication
medications(s). A severe adverse event
[30Day–08–05AJ] in peer-reviewed scientific journals to
is defined as a drug-related reaction
further describe and interpret these
Agency Forms Undergoing Paperwork resulting in hospitalization or death of
data.
Reduction Act Review a person receiving treatment for LTBI.
Deaths reported among persons with The Food and Drug Administration
The Centers for Disease Control and LTBI included, 2 of 50 persons who (FDA) collects data on adverse events
Prevention (CDC) publishes a list of were on the recommended two-month related to drugs through the FDA
information collection requests under regimen of rifampin and pyrazinamide MedWatch Program but it does not
review by the Office of Management and (RZ); 9 of 22 treated with isoniazid include the disease context and risk
Budget (OMB) in compliance with the alone, and 2 of 3 patients on other factors that are essential for revising
Paperwork Reduction Act (44 U.S.C. regimens (e.g., pyrazinamide and treatment options for LTBI. Reporting
Chapter 35). To request a copy of these ethambutol). Severe adverse events such will be conducted through telephone, e-
requests, call the CDC Reports Clearance as hospitalizations, liver transplants, mail, or during CDC site visits. There is
Officer at (404) 639–5960 or send an e- and death related to treatment of LTBI no cost to respondents other than their
mail to omb@cdc.gov. Send written continue to be reported to DTBE. time to gather medical records to
comments to CDC Desk Officer, Office of The purpose of this information complete the form. The total estimated
Management and Budget, Washington, collection request is to determine the annualized burden hours are 32.

ESTIMATED ANNUALIZED BURDEN


Average burden
Number of Number reponses
Type of respondent Form name per response
respondents per respondent (in hours)

Physician ........................................................................... AELT .......................... 4 1 3


Nurses ............................................................................... AELT .......................... 4 1 4
Medical Clerk .................................................................... AELT .......................... 4 1 1

Dated: November 6, 2007. DEPARTMENT OF HEALTH AND requests, call the CDC Reports Clearance
Maryam I. Daneshvar, HUMAN SERVICES Officer at (404) 639–5960 or send an e-
Acting Reports Clearance Officer, Centers for mail to omb@cdc.gov. Send written
Disease Control and Prevention. Centers for Disease Control and comments to CDC Desk Officer, Office of
[FR Doc. E7–22308 Filed 11–14–07; 8:45 am]
Prevention Management and Budget, Washington,
BILLING CODE 4163–18–P
DC or by fax to (202) 395–6974. Written
[30Day–08–07AU] comments should be received within 30
days of this notice.
Agency Forms Undergoing Paperwork
Reduction Act Review Proposed Project
The Centers for Disease Control and Methicillin-Resistant Staphylococcus
Prevention (CDC) publishes a list of aureus (MRSA) Infection Control
pwalker on PROD1PC71 with NOTICES

information collection requests under Practices Survey—New—National


review by the Office of Management and Center for Preparedness, Detection, and
Budget (OMB) in compliance with the Control of Infectious Diseases
Paperwork Reduction Act (44 U.S.C. (NCPDCID), Centers for Disease Control
Chapter 35). To request a copy of these and Prevention (CDC).

VerDate Aug<31>2005 19:50 Nov 14, 2007 Jkt 214001 PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 E:\FR\FM\15NON1.SGM 15NON1